Parkinson S Disease Drugs Market Size, Share, Industry Trends and Forecast to 2033
This report provides an in-depth analysis of the Parkinson's Disease drugs market, detailing key insights, market size, growth forecasts from 2023 to 2033, and trends impacting the industry.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $5.70 Billion |
| CAGR (2023-2033) | 6.3% |
| 2033 Market Size | $10.67 Billion |
| Top Companies | AbbVie Inc., Boehringer Ingelheim, UCB Pharma, Neurocrine Biosciences |
| Last Modified Date | 15 Nov 2024 |
Parkinson S Disease Drugs Market Report (2023 - 2033)
Parkinson S Disease Drugs Market Overview
What is the Market Size & CAGR of Parkinson S Disease Drugs market in 2023?
Parkinson S Disease Drugs Industry Analysis
Parkinson S Disease Drugs Market Segmentation and Scope
Request a custom research report for industry.
Parkinson S Disease Drugs Market Analysis Report by Region
Europe Parkinson S Disease Drugs Market Report:
In Europe, the market is anticipated to grow from $1.71 billion in 2023 to $3.20 billion by 2033. The uptake of therapies is supported by robust healthcare systems and increased public awareness about Parkinson's Disease management.Asia Pacific Parkinson S Disease Drugs Market Report:
In 2023, the Asia Pacific market garnered a revenue of $1.18 billion, expected to grow to $2.20 billion by 2033. Factors driving growth include rising healthcare expenditure, increasing awareness, and the prevalence of Parkinson's in rapidly aging populations in countries like Japan and China.North America Parkinson S Disease Drugs Market Report:
The North American market, the largest segment, was valued at $1.92 billion in 2023 and is forecasted to reach $3.59 billion by 2033. The region benefits from advanced healthcare systems, extensive research activities, and the availability of a wide range of treatment options.South America Parkinson S Disease Drugs Market Report:
In South America, the market was valued at $0.41 billion in 2023, with projections rising to $0.76 billion by 2033. The rise can be linked to improved healthcare infrastructure and increasing incidence rates, particularly in Brazil and Argentina.Middle East & Africa Parkinson S Disease Drugs Market Report:
The Middle East and Africa region presented a market size of $0.49 billion in 2023 with expectations to reach $0.91 billion by 2033. Factors such as improving healthcare access and increasing investments in medical research are key enablers for growth within this region.Request a custom research report for industry.
Parkinson S Disease Drugs Market Analysis By Product
Global Parkinson's Disease Drugs Market, By Product Market Analysis (2023 - 2033)
The product segment of the Parkinson's Disease drugs market includes various types of therapies. Dopamine Replacement Therapy leads with a projected market size increasing from $3.17 billion in 2023 to $5.93 billion by 2033. MAO-B inhibitors follow, growing from $1.34 billion to $2.50 billion over the same period. COMT Inhibitors and Adjunct Therapies each start at $0.60 billion in 2023, expected to double by 2033.
Parkinson S Disease Drugs Market Analysis By Therapy Type
Global Parkinson's Disease Drugs Market, By Therapy Type Market Analysis (2023 - 2033)
Dopamine replacement therapies dominate the market, comprising 55.61% of the overall share in 2023. Symptomatic therapy supports 87.67% of the treatment modalities, emphasizing its critical role in patient management. The rising emphasis on neuroprotective therapy, which holds a share of 12.33%, indicates a potential shift towards preserving neuron function in patients.
Parkinson S Disease Drugs Market Analysis By Route Of Administration
Global Parkinson's Disease Drugs Market, By Route of Administration Market Analysis (2023 - 2033)
Oral administration remains the primary route in the Parkinson's Disease drugs market, holding around 60.31% of the market share. This is followed by injectable forms (25.15%) and transdermal applications (14.54%). The growing preference for oral medications can be attributed to ease of use and better patient compliance.
Parkinson S Disease Drugs Market Analysis By Distribution Channel
Global Parkinson's Disease Drugs Market, By Distribution Channel Market Analysis (2023 - 2033)
The distribution channels encompass hospital pharmacies (60.31%), retail (25.15%), and online pharmacies (14.54%). Hospital pharmacies will continue to be the dominant channel owing to their close association with healthcare providers and prescriptions issued during hospital stays.
Parkinson S Disease Drugs Market Analysis By End User
Global Parkinson's Disease Drugs Market, By End-User Market Analysis (2023 - 2033)
The end-users of Parkinson's disease drugs include hospitals, clinics, and homecare settings. Hospitals lead the sector with 60.31% of the market share, followed by clinics (25.15%) and homecare solutions (14.54%), indicating a dominant trend towards hospitalization for treatment.
Parkinson S Disease Drugs Market Trends and Future Forecast
Request a custom research report for industry.
Global Market Leaders and Top Companies in Parkinson S Disease Drugs Industry
AbbVie Inc.:
AbbVie is a research-based biopharmaceutical company known for producing high-quality Parkinson's Disease therapies like Duopa and Nobivon.Boehringer Ingelheim:
Boehringer Ingelheim specializes in innovative medicines for the treatment of Parkinson’s Disease, leading advancements in therapeutic options.UCB Pharma:
UCB Pharma focuses on individual patient needs and advancing Parkinson’s treatments through significant research and development investments.Neurocrine Biosciences:
Neurocrine Biosciences targets chemical innovations that improve patient quality of life with its unique treatments for Parkinson's Disease.We're grateful to work with incredible clients.
